Alkermes (ALKS) Expected to Release Earnings on Tuesday

Alkermes (NASDAQ:ALKS) will likely be issuing its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect Alkermes to post earnings of ($0.04) per share and revenue of $457.4070 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:00 AM ET.

Alkermes Stock Down 0.2%

Shares of NASDAQ:ALKS opened at $52.89 on Friday. The stock’s 50-day moving average price is $46.92 and its 200-day moving average price is $37.44. Alkermes has a 12-month low of $25.17 and a 12-month high of $55.67. The stock has a market capitalization of $8.82 billion, a P/E ratio of 58.77 and a beta of 0.34. The company has a current ratio of 2.27, a quick ratio of 1.70 and a debt-to-equity ratio of 0.85.

Insider Activity

In related news, EVP David Joseph Gaffin sold 2,034 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $43.05, for a total transaction of $87,563.70. Following the completion of the transaction, the executive vice president owned 229,524 shares in the company, valued at $9,881,008.20. This represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig C. Hopkinson sold 9,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $51.51, for a total value of $463,590.00. Following the completion of the sale, the executive vice president directly owned 73,389 shares of the company’s stock, valued at $3,780,267.39. The trade was a 10.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 35,102 shares of company stock valued at $1,494,410. Company insiders own 4.59% of the company’s stock.

Institutional Investors Weigh In On Alkermes

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Johnson Financial Group Inc. purchased a new position in Alkermes during the third quarter valued at $31,000. UMB Bank n.a. increased its stake in shares of Alkermes by 57.6% in the 4th quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock worth $34,000 after acquiring an additional 446 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in shares of Alkermes by 1,041.4% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,324 shares of the company’s stock worth $37,000 after acquiring an additional 1,208 shares in the last quarter. Osaic Holdings Inc. lifted its position in Alkermes by 56.4% during the 2nd quarter. Osaic Holdings Inc. now owns 1,945 shares of the company’s stock valued at $56,000 after acquiring an additional 701 shares during the period. Finally, T. Rowe Price Investment Management Inc. purchased a new position in Alkermes during the 4th quarter valued at about $59,000. 95.21% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ALKS has been the subject of several analyst reports. JPMorgan Chase & Co. initiated coverage on Alkermes in a report on Monday, July 13th. They set a “neutral” rating and a $60.00 target price for the company. TD Cowen boosted their price objective on Alkermes from $42.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Mizuho increased their price objective on Alkermes from $53.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, July 2nd. Weiss Ratings cut shares of Alkermes from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Finally, HC Wainwright restated a “neutral” rating on shares of Alkermes in a report on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $52.50.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.